Delta Resources Ltd. logo

Delta Resources Ltd. (6GO1)

Market Closed
7 Aug, 20:00
XFRA XFRA
0. 09
-0
-3.1088%
13.56M Market Cap
- P/E Ratio
- Div Yield
90,000 Volume
- Eps
0.1
Previous Close
Add Transaction
Day Range
0.09 0.09
Year Range
0.04 0.16
Want to track 6GO1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

6GO1 closed Friday lower at €0.09, a decrease of -3.1088% from Thursday's close, completing a monthly increase of 3.8889% or €0. Over the past 12 months, 6GO1 stock gained 2.7473%.
6GO1 is not paying dividends to its shareholders.
The last earnings report, released on Apr 09, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Delta Resources Ltd. has completed 1 stock splits, with the recent split occurring on Dec 01, 2014.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on TSX-V (CAD).

6GO1 Chart

People also search for

DCV
Advanex Inc.
13.6
+0.7407%
OKYO Pharma Limited
1.36
0%
78W
Modulight Oyj
1.05
-0.4739%
3NQ
Nano mRNA Co., Ltd.
0.55
0%
PGT
StrongPoint ASA
0.84
-0.237%

Delta Resources Ltd. (6GO1) FAQ

What is the stock price today?

The current price is €0.09.

On which exchange is it traded?

Delta Resources Ltd. is listed on XFRA.

What is its stock symbol?

The ticker symbol is 6GO1.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 13.56M.

Has Delta Resources Ltd. ever had a stock split?

Delta Resources Ltd. had 1 splits and the recent split was on Dec 01, 2014.

Delta Resources Ltd. Profile

Health Care Technology Industry
Healthcare Sector
Dr. Richard Allman Ph.D. CEO
XFRA Exchange
CA24780P1009 ISIN
Australia Country
- Employees
- Last Dividend
1 Dec 2014 Last Split
- IPO Date

Overview

Cleo Diagnostics Ltd is a pioneering medical diagnostics and devices company established in 2021 and headquartered in Melbourne, Australia. The core mission of Cleo Diagnostics is centered around the development and commercialization of non-invasive blood tests for the early detection of ovarian cancer. By focusing on innovative and accessible diagnostic solutions, the company aims to significantly improve early detection rates and outcomes for individuals at risk of ovarian cancer in Australia. Cleo Diagnostics is also dedicated to the advancement of its research and development efforts, working on securing intellectual property and patents to underpin its diagnostic technologies.

Products and Services

  • CleoDX Pre-Surgical Triage Tests
  • This cutting-edge diagnostic tool offered by Cleo Diagnostics represents a significant advancement in the management of ovarian cancer. The CleoDX test utilizes a proprietary combination of serum biomarkers to accurately assess the malignancy risk associated with ovarian tumors. Designed to be administered prior to surgical referral, this non-invasive blood test aims to improve the decision-making process for medical professionals, ensuring that patients receive the most appropriate level of care based on their individual risk assessment.

Contact Information

Address: 480 Collins Street
Phone: 61 3 9614 0600